Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
ATHA Stock Chart & Stats
$7.40
-$0.02(-3.33%)
At close: 4:00 PM EST
$7.40
-$0.02(-3.33%)
Day’s Range― - ―
52-Week Range$2.19 - $6.09
Previous CloseN/A
Volume52.95K
Average Volume (3M)41.47K
Market Cap
$29.18M
Enterprise Value-$17.00M
Total Cash (Recent Filing)$25.23M
Total Debt (Recent Filing)$912.00K
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 19, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding3,943,887
10 Day Avg. Volume36,543
30 Day Avg. Volume41,474
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit24.78
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$4.00Price Target Upside-45.95% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentATH-1105 has demonstrated a favorable safety profile and was well-tolerated in a Phase 1 study, supporting continued clinical development.
Financial StabilityThere is now sufficient cash runway to support operations through the data readout following the company's restructuring and downsizing.
Regulatory EnvironmentThe development pathway for ALS is attractive due to the FDA's flexibility and recent accelerated approval of Tofersen using Nf-L as a surrogate biomarker.
Bears Say
Financial ChallengesGiven the discontinuation of fosgonimeton, ATHA has significantly restructured and reduced future operating expenses, indicating financial challenges.
Partnership ChallengesThe company is unlikely to advance the program without a partner, and a partnership is unlikely to materialize due to the challenging ALS space and negative data for prior lead asset.
Strategic UncertaintyA strategic transaction for ATHA could ultimately result, but visibility on when and with whom is low, leading analysts to recommend looking elsewhere for growth opportunities.
Athira Pharma News
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $2.19 and its highest was $6.09 in the past 12 months.
What is Athira Pharma’s market cap?
Athira Pharma’s market cap is $29.18M.
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Mar 19, 2026 which is in 85 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on Nov 06, 2025. The company reported -$1.68 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.62.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Overvalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -0.58.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 3,943,887 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$1.68 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -3.99%.
Which hedge fund is a major shareholder of Athira Pharma?
Currently, no hedge funds are holding shares in ATHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Athira Pharma
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
ATHA Stock 12 Month Forecast
Average Price Target
$4.00
▼(-45.95% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---